Semaglutide
Sold as Ozempic, Rybelsus, Wegovy, Semagard
No structure available
This product's active ingredient could not be matched to a single known compound.
Background
Registration
- Applicants
- 2
- Registrations
- 10
- Schedule source
- SAHPRA documentation
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Novo Nordisk (Pty) Ltd û (Rivonia)Certificate held by Novo Nordisk (Pty) Ltd | Ozempic, Rybelsus, Wegovy | 0,25 mg and 0,5 mg, 0,25 mg, 0,5 mg, 1 mg, 1,7 mg, 2,4 mg, 3 mg, 7 mg, 14 mg | 530497, 560337, 560338, 560339, 580223, 580224, 580225, 580226, 580227 | S4 | PIPIL |
| Ranbaxy Pharmaceutical (Pty) LtdCertificate held by Ranbaxy Pharmaceuticals (Pty) Ltd | Semagard | 2 mg, 4 mg, 1,34 mg | 610768 | S4 | PIPIL |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ozempic EACH 1,0 ml SOLUTION CONTAINS SEMAGLUTIDE 1,34 mg | 0,25 mg and 0,5 mgSolution for injection (injection). | 53049753/21.13/0497Approved 17 February 2022 | Registered | S4 | PIPIL |
| Rybelsus 3 MG EACH TABLET CONTAINS SEMAGLUTIDE 3,0 mg | 3 mg | 56033756/21.13/0337 | Registered | S4 | None |
| Rybelsus 7 MG EACH TABLET CONTAINS SEMAGLUTIDE 7,0 mg | 7 mg | 56033856/21.13/0338 | Registered | S4 | None |
| Rybelsus 14 MG EACH TABLET CONTAINS SEMAGLUTIDE 14,0 mg | 14 mg | 56033956/21.13/0339 | Registered | S4 | None |
| Wegovy 0,25 MG EACH DOSE CONTAINS SEMAGLUTIDE 0,25 mg | 0,25 mg | 58022358/21.013/0223 | Registered | S4 | None |
| Wegovy 0,5 MG EACH DOSE CONTAINS SEMAGLUTIDE 0,5 mg | 0,5 mg | 58022458/21.013/0224 | Registered | S4 | None |
| Wegovy 1 MG EACH DOSE CONTAINS SEMAGLUTIDE 1 mg | 1 mg | 58022558/21.013/0225 | Registered | S4 | None |
| Wegovy 1,7 MG EACH DOSE CONTAINS SEMAGLUTIDE 1,7 mg | 1,7 mg | 58022658/21.013/0226 | Registered | S4 | None |
| Wegovy 2,4 MG EACH DOSE CONTAINS SEMAGLUTIDE 2,4 mg | 2,4 mg | 58022758/21.013/0227 | Registered | S4 | None |
| Semagard EACH 1,0 ml SOLUTION CONTAINS: SEMAGLUTIDE 1,34 mg | 2 mg, 4 mg, 1,34 mgSolution for injection | 61076861/21.13/0768Approved 30 June 2026 | Registered | S4 | PIPIL |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, read from the product's PI-PIL leaflet.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Semaglutide
S4: Semaglutide
Consolidated Schedules 06 July 2026, line 7910
Pharmacological class: Others. (class 21.13)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule Verification
Ozempic, Novo Nordisk (Pty) Ltd û (Rivonia) is scheduled S4 in its official SAHPRA documents, read with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.